HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IRD

Opus Genetics Inc

Last Close
Dec 31  •  04:00PM ET
2.01
Dollar change
+0.06
Percentage change
3.08 %
Healthcare • Biotechnology • USA • NASD
Held by: VTI VXF BSVO
Index- P/E- EPS (ttm)-1.72 Insider Own20.92% Shs Outstand64.54M Perf Week0.00%
Market Cap138.62M Forward P/E- EPS next Y-0.38 Insider Trans-21.00% Shs Float54.54M Perf Month0.50%
Enterprise Value108.87M PEG- EPS next Q-0.11 Inst Own22.29% Short Float1.17% Perf Quarter11.67%
Income-68.20M P/S9.48 EPS this Y68.70% Inst Trans-5.08% Short Ratio1.25 Perf Half Y103.03%
Sales14.63M P/B21.74 EPS next Y43.39% ROA-178.28% Short Interest0.64M Perf YTD68.91%
Book/sh0.09 P/C4.50 EPS next 5Y42.72% ROE-338.75% 52W High2.59 -22.41% Perf Year70.34%
Cash/sh0.45 P/FCF- EPS past 3/5Y17.37% 24.32% ROIC-969.48% 52W Low0.65 209.23% Perf 3Y-19.92%
Dividend Est.- EV/EBITDA- Sales past 3/5Y165.25% - Gross Margin99.66% Volatility4.75% 6.34% Perf 5Y-63.59%
Dividend TTM- EV/Sales7.44 EPS Y/Y TTM-58.14% Oper. Margin-254.05% ATR (14)0.13 Perf 10Y-98.90%
Dividend Ex-Date- Quick Ratio1.23 Sales Y/Y TTM74.60% Profit Margin-466.09% RSI (14)46.53 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.23 EPS Q/Q14.17% SMA20-6.34% Beta0.41 Target Price7.80
Payout- Debt/Eq0.18 Sales Q/Q-20.38% SMA50-1.99% Rel Volume0.42 Prev Close1.95
Employees18 LT Debt/Eq0.18 EarningsNov 12 BMO SMA20044.70% Avg Volume509.25K Price2.01
IPONov 30, 2004 Option/ShortYes / Yes EPS/Sales Surpr.-92.31% 0.25% Trades Volume212,948 Change3.08%
Date Action Analyst Rating Change Price Target Change
Dec-10-25Initiated B. Riley Securities Buy $9
Nov-25-25Initiated Piper Sandler Overweight $7
Oct-29-25Initiated Wedbush Outperform $8
Oct-16-25Initiated Chardan Capital Markets Buy $9
Apr-11-25Initiated Craig Hallum Buy $6
Nov-13-24Resumed H.C. Wainwright Buy $8
Dec-20-25 12:00PM
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
(Barchart)
Dec-16-25 04:01PM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.61%
Dec-11-25 07:00AM
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
(GlobeNewswire)
Dec-09-25 07:00AM
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
(GlobeNewswire)
Dec-02-25 04:01PM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.03%
01:26AM Loading…
Nov-29-25 01:26AM
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With "Overweight" Rating and $7 PT
(Insider Monkey)
Nov-20-25 08:00AM
Opus Genetics to Participate in Upcoming Investment Conferences
(GlobeNewswire)
Nov-13-25 07:00AM
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
(GlobeNewswire)
Nov-12-25 08:30AM
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
(Zacks)
07:00AM
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
(GlobeNewswire)
Nov-06-25 05:35PM
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
07:00AM
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
(GlobeNewswire)
07:00AM
Opus Genetics Announces $23 Million Registered Direct Offering
(GlobeNewswire)
Nov-05-25 10:00AM
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
(Zacks)
07:40AM
Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates
(Zacks)
05:15PM Loading…
Nov-04-25 05:15PM
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
(Zacks)
04:01PM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
10:00AM
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
(Zacks)
Nov-03-25 08:00AM
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
(GlobeNewswire) -6.96%
Oct-14-25 08:00AM
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
(GlobeNewswire)
Oct-02-25 08:00AM
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
(GlobeNewswire)
Oct-01-25 12:00PM
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice
(Zacks) +9.09%
Sep-30-25 07:00AM
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
(GlobeNewswire) -7.82%
Sep-16-25 03:42AM
Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics
(Zacks)
Sep-15-25 03:00PM
The Under $20 Breakout Trio Investors Shouldn't Ignore
(Zacks)
Sep-12-25 08:00AM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-04-25 08:00AM
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
(GlobeNewswire)
Sep-03-25 08:00AM
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
(GlobeNewswire)
Sep-02-25 08:00AM
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
(GlobeNewswire)
Aug-27-25 08:00AM
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
(GlobeNewswire)
08:00AM Loading…
Aug-18-25 08:00AM
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
(GlobeNewswire)
Aug-13-25 05:40PM
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
(Zacks) +7.27%
04:30PM
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
(GlobeNewswire)
Aug-07-25 08:25AM
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
Aug-05-25 08:00AM
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
(GlobeNewswire)
Jul-23-25 08:00AM
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
(GlobeNewswire)
Jul-10-25 09:31AM
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
(Zacks)
Jul-03-25 04:30PM
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-26-25 06:55AM
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
(GlobeNewswire) +5.13%
Jun-23-25 08:00AM
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
(GlobeNewswire)
Jun-02-25 08:00AM
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
(GlobeNewswire) +9.60%
May-15-25 09:15AM
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
08:00AM
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
(GlobeNewswire)
May-14-25 06:55PM
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-13-25 08:45AM
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-12-25 08:00AM
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
(GlobeNewswire)
May-08-25 09:25AM
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
May-06-25 08:00AM
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
(GlobeNewswire)
May-05-25 08:00AM
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
(GlobeNewswire)
May-02-25 10:00AM
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
(Zacks)
Apr-15-25 10:36AM
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
(GlobeNewswire)
Apr-11-25 03:47PM
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns
(GlobeNewswire)
Apr-08-25 08:00AM
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
(GlobeNewswire) -11.50%
Apr-07-25 08:00AM
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress
(GlobeNewswire)
Apr-02-25 08:00AM
Opus Genetics to Participate in Upcoming Investor Conference in April
(GlobeNewswire)
Mar-31-25 08:20AM
Opus Genetics Announces Financial Results for Full Year 2024
(GlobeNewswire)
Mar-21-25 05:03PM
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics
(GlobeNewswire) +9.57% -8.73%
09:30AM
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
(GlobeNewswire)
09:11AM
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
(GlobeNewswire)
Mar-19-25 03:56PM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-05-25 08:00AM
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
(GlobeNewswire)
Feb-26-25 08:00AM
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
(GlobeNewswire)
Feb-18-25 07:30AM
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
(GlobeNewswire)
Feb-07-25 09:15AM
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
(GlobeNewswire) -5.74%
Dec-19-24 08:00AM
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
(GlobeNewswire) +18.93%
Dec-03-24 08:00AM
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
(GlobeNewswire) +5.22%
Nov-14-24 06:40AM
Opus Genetics reinstated with a Buy at H.C. Wainwright
(TipRanks)
Nov-12-24 08:00AM
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
(GlobeNewswire)
07:59AM
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-25-24 12:00PM
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
(PR Newswire)
Oct-23-24 05:31PM
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics
(TipRanks) -12.03%
Oct-22-24 04:05PM
Ocuphire Pharma Announces Acquisition of Opus Genetics
(GlobeNewswire)
Sep-30-24 08:00AM
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
(GlobeNewswire)
Sep-05-24 08:43PM
UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
(GlobeNewswire)
08:00AM
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
(GlobeNewswire)
Aug-13-24 08:00AM
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
(GlobeNewswire) -20.85%
Aug-08-24 08:00AM
Ocuphire Pharma to Present at Two Investor Conferences in August
(GlobeNewswire) +6.10%
Jul-10-24 08:00AM
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
(GlobeNewswire) +6.45%
Jun-06-24 07:57AM
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
(GlobeNewswire)
May-10-24 01:53PM
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace) -12.24%
08:00AM
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
(GlobeNewswire)
May-06-24 08:00AM
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
(GlobeNewswire)
May-03-24 08:00AM
Ocuphire Pharma to Present at the Aegis Virtual Conference
(GlobeNewswire) +7.57%
Apr-22-24 08:00AM
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
(GlobeNewswire) -8.76%
Apr-11-24 10:03AM
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
(GlobeNewswire)
Apr-01-24 07:14AM
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
(GlobeNewswire) +10.95%
Mar-15-24 11:53AM
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
Mar-09-24 01:09PM
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
(Insider Monkey)
Mar-08-24 08:00AM
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
(GlobeNewswire) -16.39%
Mar-04-24 08:18AM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
(Zacks)
Feb-23-24 08:00AM
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
(GlobeNewswire)
Feb-15-24 04:10PM
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-14-24 08:00AM
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
(GlobeNewswire)
Feb-05-24 08:00AM
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
(GlobeNewswire)
Jan-24-24 04:10PM
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-11-24 07:41AM
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
(Zacks) -7.81%
Jan-04-24 08:00AM
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
(GlobeNewswire)
Nov-30-23 08:00AM
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
(GlobeNewswire) +11.31%
Nov-27-23 04:38PM
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
08:00AM
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
(GlobeNewswire)
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher CamDirectorDec 29 '25Buy1.9783,000163,41983,000Dec 31 04:33 PM
Gallagher CamDirectorDec 29 '25Buy1.9881,000160,2751,891,430Dec 31 04:33 PM
Foundation Fighting Blindness DirectorDec 09 '25Sale2.154,000,0008,600,0005,492,171Dec 11 05:35 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ZNTL

Zentalis Pharmaceuticals Inc

Last Close
Dec 31  •  04:00PM ET
1.35
Dollar change
+0.02
Percentage change
1.50 %
Healthcare • Biotechnology • USA • NASD
ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart
Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN
 | Held by: VTI VXF FESM PRFZ VHT IWC FSCC AVSC BTEC MSSM
Index- P/E- EPS (ttm)-2.08 Insider Own17.65% Shs Outstand72.25M Perf Week0.00%
Market Cap97.54M Forward P/E- EPS next Y-1.69 Insider Trans-37.03% Shs Float59.50M Perf Month-1.46%
Enterprise Value-142.70M PEG- EPS next Q-0.43 Inst Own65.06% Short Float9.24% Perf Quarter-12.34%
Income-149.32M P/S3.63 EPS this Y21.73% Inst Trans-3.97% Short Ratio7.77 Perf Half Y8.87%
Sales26.86M P/B0.39 EPS next Y7.27% ROA-38.39% Short Interest5.50M Perf YTD-55.45%
Book/sh3.50 P/C0.35 EPS next 5Y11.41% ROE-49.18% 52W High3.33 -59.46% Perf Year-55.88%
Cash/sh3.89 P/FCF- EPS past 3/5Y14.39% -12.89% ROIC-51.56% 52W Low1.01 33.66% Perf 3Y-92.61%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin96.65% Volatility3.24% 4.68% Perf 5Y-97.64%
Dividend TTM- EV/Sales-5.31 EPS Y/Y TTM17.54% Oper. Margin-567.95% ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.76 Sales Y/Y TTM-33.76% Profit Margin-555.80% RSI (14)45.44 Recom2.00
Dividend Gr. 3/5Y- - Current Ratio7.76 EPS Q/Q34.48% SMA20-2.53% Beta1.75 Target Price5.71
Payout- Debt/Eq0.16 Sales Q/Q- SMA50-4.55% Rel Volume0.86 Prev Close1.33
Employees166 LT Debt/Eq0.15 EarningsNov 10 AMC SMA200-6.55% Avg Volume707.67K Price1.35
IPOApr 03, 2020 Option/ShortYes / Yes EPS/Sales Surpr.29.90% - Trades Volume606,232 Change1.50%
Date Action Analyst Rating Change Price Target Change
Aug-12-24Upgrade Wedbush Underperform → Neutral $4
Jun-20-24Downgrade UBS Buy → Neutral $28 → $5
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Show Previous Ratings
Nov-10-25 04:05PM
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +6.06%
Nov-03-25 05:25PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.33%
08:15AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Oct-13-25 04:05PM
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-01-25 05:20PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +7.79%
05:00PM Loading…
Sep-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Aug-28-25 04:15PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-26-25 04:05PM
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
(GlobeNewswire)
Aug-06-25 04:05PM
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.07%
Jul-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.88%
May-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-28-25 08:00AM
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
(GlobeNewswire)
Apr-23-25 04:05PM
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
(GlobeNewswire)
05:30PM Loading…
Apr-01-25 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -12.58%
Mar-26-25 04:05PM
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
(GlobeNewswire) -5.88%
Mar-25-25 04:40PM
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
(GlobeNewswire) -5.56%
Mar-15-25 11:25AM
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Mar-03-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -7.25%
08:00AM
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Feb-24-25 04:05PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-21-25 12:21AM
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
(Insider Monkey) -6.07%
Feb-03-25 05:42PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
09:35AM
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-30-25 10:20AM
Zentalis price target lowered to $10 from $20 at Oppenheimer
(TipRanks) -12.17%
Jan-29-25 07:00AM
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
(GlobeNewswire) -21.25%
Jan-28-25 04:05PM
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
(GlobeNewswire)
Jan-09-25 12:00PM
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks)
07:00AM
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
(GlobeNewswire)
04:53PM Loading…
Jan-02-25 04:53PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.00%
Dec-12-24 07:00AM
Zentalis Pharmaceuticals Announces Key Management Appointments
(GlobeNewswire) -10.57%
Dec-02-24 04:35PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.20%
Nov-13-24 08:00AM
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
(GlobeNewswire) +5.66%
Nov-01-24 07:04PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
(GuruFocus.com)
Oct-07-24 03:03PM
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
(GuruFocus.com) -7.72%
Sep-17-24 12:15PM
FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor
(Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
(Benzinga) +13.58%
07:00AM
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
(GlobeNewswire)
Sep-09-24 07:00AM
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
(GlobeNewswire)
Sep-03-24 04:40PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.92%
Aug-26-24 11:58AM
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
(Zacks)
Aug-09-24 02:53PM
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024
(InvestorPlace) -9.37%
07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
Aug-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.00%
Jul-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -14.80%
Jun-19-24 10:23AM
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
(Zacks)
04:52AM
FDA places partial clinical hold on Zentalis trials of azenosertib for cancer
(Clinical Trials Arena)
Jun-18-24 07:00AM
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
(GlobeNewswire) -50.66%
Jun-03-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-01-24 02:43AM
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
(GuruFocus.com)
May-30-24 07:00AM
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-29-24 07:00AM
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
(GlobeNewswire)
May-23-24 05:01PM
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
(GlobeNewswire) -5.84%
May-14-24 07:00AM
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
(GlobeNewswire)
May-08-24 10:27AM
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
(MT Newswires)
May-07-24 09:04PM
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
(GuruFocus.com) +5.03%
01:54PM
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
May-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-02-24 04:05PM
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
(GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-28-24 09:55AM
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
(Zacks) +5.30%
07:00AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-27-24 07:01PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
(GuruFocus.com)
07:00AM
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
(GlobeNewswire)
Feb-14-24 09:35AM
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
(Zacks) +10.34%
Feb-13-24 07:00AM
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
(GlobeNewswire) -5.83%
Feb-08-24 12:00PM
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
(Zacks)
Feb-05-24 11:26PM
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Feb-01-24 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-25-24 07:00AM
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
(GlobeNewswire)
Jan-08-24 07:00AM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
(Business Wire) +7.15%
Jan-02-24 04:49PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.54%
Dec-01-23 05:39PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-13-23 09:03PM
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares
(GuruFocus.com) +14.42%
Nov-09-23 07:00AM
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
(GlobeNewswire)
Nov-06-23 07:13PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
(GuruFocus.com) -30.20% -18.27%
07:18AM
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Nov-01-23 04:52PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-07-23 05:00AM
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...
(GuruFocus.com)
Oct-02-23 04:27PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-14-23 01:02AM
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Sep-06-23 07:00AM
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire)
Sep-01-23 04:37PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.34%
Aug-09-23 07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Aug-01-23 04:28PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
(GlobeNewswire)
Jun-15-23 06:01AM
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
(GlobeNewswire) +12.67%
Jun-06-23 06:00AM
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
(GlobeNewswire)
Jun-02-23 02:34PM
Why Shares of Zentalis Pharmaceuticals Dropped This Week
(Motley Fool)
May-26-23 12:33PM
Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside
(TipRanks) +10.64%
10:53AM
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
(Benzinga)
May-25-23 05:38PM
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
(GlobeNewswire)
May-23-23 07:00AM
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
(GlobeNewswire)
May-12-23 09:55AM
Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
(Zacks)
May-10-23 07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire) +6.93%
Apr-26-23 10:00AM
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
(GlobeNewswire)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matrix Capital Management Comp10% OwnerDec 15 '25Sale1.337,500,0009,975,0006,459,973Dec 15 05:24 PM
Myers Scott DunsethDirectorApr 30 '25Buy1.4021,00029,373281,192Apr 30 05:07 PM
Bruns IngmarChief Medical OfficerFeb 06 '25Buy2.2820,00045,65636,629Feb 12 05:00 PM
Cam GallagherFormer DirectorFeb 11 '25Proposed Sale2.006871,374Feb 11 08:06 PM
Vultaggio VincentPAO and Interim PFOFeb 03 '25Sale1.712,6154,476189,826Feb 05 06:33 PM
Lackner MarkChief Scientific OfficerFeb 03 '25Sale1.7114,36824,591512,856Feb 05 06:32 PM
Paul AndreaChief Legal OfficerFeb 03 '25Sale1.7113,23022,6431,070,784Feb 05 06:31 PM
Skvarka JanDirectorJan 31 '25Buy1.7260,000103,446149,551Feb 04 04:45 PM
Walker Luke NathanielDirectorJan 31 '25Buy1.7614,20024,96686,681Feb 04 04:43 PM
EASTLAND JULIA MARIECEO & PresidentJan 31 '25Buy1.7328,50049,34528,500Feb 04 04:37 PM
Mark LacknerChief Scientific OfficerFeb 03 '25Proposed Sale1.7114,36824,591Feb 03 07:14 PM
Andrea PaulChief Legal Officer & CorporatFeb 03 '25Proposed Sale1.7113,23022,643Feb 03 07:13 PM
Cam GallagherFormer DirectorFeb 03 '25Proposed Sale1.7128,55848,877Feb 03 07:12 PM
Lackner MarkChief Scientific OfficerJan 02 '25Sale3.124,41113,762191,317Jan 03 05:17 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.